Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.

Tytuł :
Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.
Autorzy :
Lustberg MB
Stover DG
Chalmers JJ
Pokaż więcej
Źródło :
Cancer journal (Sudbury, Mass.) [Cancer J] 2018 Mar/Apr; Vol. 24 (2), pp. 61-64.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
Język :
English
Imprint Name(s) :
Publication: 2007- : Sudbury, MA : Lippincott Williams & Wilkins
Original Publication: Sudbury, MA : Jones and Bartlett Publishers, c2000-
MeSH Terms :
Biomarkers, Tumor/*metabolism
Liquid Biopsy/*methods
Neoplasms/*metabolism
Neoplasms/*pathology
Clinical Trials as Topic ; Humans ; Precision Medicine/methods
References :
EMBO Mol Med. 2014 Oct 30;6(11):1371-86. (PMID: 25358515)
Sci Transl Med. 2015 Nov 11;7(313):313ra182. (PMID: 26560360)
Mol Aspects Med. 2018 Apr;60:27-37. (PMID: 29155161)
Front Oncol. 2012 Oct 25;2:128. (PMID: 23112954)
Nat Commun. 2017 Nov 6;8(1):1324. (PMID: 29109393)
Clin Cancer Res. 2008 Oct 1;14(19):6302-9. (PMID: 18829513)
Methods Mol Biol. 2016;1379:45-68. (PMID: 26608289)
C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3. (PMID: 18875018)
Clin Cancer Res. 2010 Nov 1;16(21):5233-43. (PMID: 20978147)
Prostate Cancer Prostatic Dis. 2000 Jul;3(1):21-27. (PMID: 12497157)
Nat Rev Cancer. 2011 Jun;11(6):426-37. (PMID: 21562580)
Sci Transl Med. 2015 Aug 26;7(302):302ra133. (PMID: 26311728)
Nat Commun. 2015 Nov 04;6:8760. (PMID: 26530965)
Nat Med. 2008 Sep;14(9):985-90. (PMID: 18670422)
JAMA Oncol. 2017 Dec 14;:null. (PMID: 29242909)
Methods Mol Biol. 2017;1634:219-234. (PMID: 28819855)
J Clin Oncol. 2014 Nov 1;32(31):3483-9. (PMID: 24888818)
Clin Cancer Res. 2008 Apr 1;14(7):1938-46. (PMID: 18381931)
Sci Transl Med. 2012 May 30;4(136):136ra68. (PMID: 22649089)
Breast Cancer Res. 2014 Aug 09;16(4):421. (PMID: 25107527)
Lung Cancer. 2012 Feb;75(2):242-7. (PMID: 21820198)
Clin Cancer Res. 2002 Dec;8(12):3761-6. (PMID: 12473587)
Cancer Discov. 2015 Oct;5(10):1040-8. (PMID: 26109333)
Biotechnol Bioeng. 2009 Feb 1;102(2):521-34. (PMID: 18726961)
N Engl J Med. 2014 Sep 11;371(11):1028-38. (PMID: 25184630)
Nat Rev Cancer. 2014 Sep;14 (9):623-31. (PMID: 25154812)
Clin Cancer Res. 2010 Mar 15;16(6):1745-55. (PMID: 20215558)
Mol Oncol. 2015 Nov;9(9):1773-82. (PMID: 26093818)
J Clin Oncol. 2016 Sep 1;34(25):2961-8. (PMID: 27269946)
Cancer Discov. 2016 Aug;6(8):838-851. (PMID: 27179038)
N Engl J Med. 2004 Aug 19;351(8):781-91. (PMID: 15317891)
Ann Oncol. 2014 Oct;25(10 ):1959-65. (PMID: 25185240)
Sci Transl Med. 2013 Jul 31;5(196):196cm6. (PMID: 23903752)
Ann Oncol. 2009 Jul;20(7):1223-9. (PMID: 19282466)
Clin Cancer Res. 2017 Oct 15;23 (20):6305-6314. (PMID: 28710315)
Front Oncol. 2016 Nov 08;6:234. (PMID: 27878106)
Clin Cancer Res. 2010 Feb 1;16(3):1073-84. (PMID: 20103672)
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8. (PMID: 15194824)
Nat Biotechnol. 2008 Apr;26(4):400-1. (PMID: 18392022)
Cancer Treat Rev. 2011 Dec;37(8):579-89. (PMID: 21592671)
Clin Cancer Res. 2016 Feb 15;22(4):915-22. (PMID: 26459174)
Nature. 2013 May 2;497(7447):108-12. (PMID: 23563269)
N Engl J Med. 2013 Mar 28;368(13):1199-209. (PMID: 23484797)
BMC Cancer. 2016 Sep 22;16(1):744. (PMID: 27658492)
Ann Oncol. 2018 Jan 1;29(1):193-199. (PMID: 29361135)
Cancer Res. 1977 Mar;37(3):646-50. (PMID: 837366)
Nat Rev Rheumatol. 2010 Jul;6(7):391-8. (PMID: 20517293)
Breast Cancer Res. 2014 Mar 06;16(2):R23. (PMID: 24602188)
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1274-9. (PMID: 21173379)
Clin Cancer Res. 2010 May 1;16(9):2634-45. (PMID: 20406831)
Mol Cancer Ther. 2017 Jul;16(7):1412-1420. (PMID: 28446639)
Clin Cancer Res. 2012 Jun 15;18(12):3462-9. (PMID: 22421194)
Grant Information :
P30 CA016058 United States CA NCI NIH HHS; R01 CA097391 United States CA NCI NIH HHS; R01 HL131720 United States HL NHLBI NIH HHS
Substance Nomenclature :
0 (Biomarkers, Tumor)
Entry Date(s) :
Date Created: 20180331 Date Completed: 20190321 Latest Revision: 20190321
Update Code :
20210301
PubMed Central ID :
PMC5880324
DOI :
10.1097/PPO.0000000000000309
PMID :
29601331
Czasopismo naukowe
A primary goal of personalized medicine is to develop tumor-specific biomarkers to aid in treatment selection and to better evaluate response to targeted therapies. The assessment of circulating blood markers as surrogate real-time biopsies of disease status, termed liquid biopsies, has been under investigation. There are many different types of liquid biopsies each with different functionalities and limitations. These include tumor markers, circulating tumor cells, cell-free DNA, and extracellular vesicles including exosomes. Multiple clinical trials have evaluated liquid biopsies as prognostic biomarkers with positive results. Additional studies are underway to evaluate liquid biopsies as predictive biomarkers, pharmacodynamic biomarkers, and surrogate efficacy endpoints for treatment response evaluation. There are several challenges in and barriers to implementation of liquid biopsies into clinical trials and subsequently into routine clinical practice, which are addressed in this review.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies